Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Viyash Scientific Limited specializes in the development and manufacturing of specialty pharmaceuticals, particularly in oncology and rare diseases. With a robust pipeline of over 30 products in various stages of development, the company leverages its advanced R&D capabilities and strategic partnerships to maintain a competitive edge in the rapidly evolving healthcare landscape.
Viyash generates revenue primarily through the sale of specialty pharmaceuticals, which command higher margins due to their complex manufacturing processes and limited competition. The company benefits from strong pricing power in niche markets and has established long-term contracts with healthcare providers and distributors.
FDA approvals for new specialty drugs
Partnership announcements with larger pharmaceutical companies
Changes in healthcare regulations affecting drug pricing
Market expansion into emerging economies
Regulatory changes that could impact drug pricing and reimbursement
Technological disruption in drug development processes
Increased competition from generic drug manufacturers
Emergence of biosimilars in the specialty drug market
Potential liquidity issues if cash flow from operations declines
Rising costs associated with R&D and compliance
moderate - Viyash's performance is somewhat linked to healthcare spending, which can be influenced by economic cycles, but the demand for specialty drugs tends to remain stable even during downturns.
Interest rates have a limited direct impact on Viyash, but rising rates could increase the cost of capital for R&D investments, potentially affecting growth plans.
minimal - The company has a low debt-to-equity ratio of 0.17, indicating a strong balance sheet and limited reliance on external financing.
growth - Investors are likely attracted to Viyash due to its rapid revenue growth and strong pipeline of specialty drugs.
high - The stock has shown significant price volatility, evidenced by a 50.5% return over the past three months.
